• CH 223191: Reading the AhR–Gut Evidence

  2026-10-07

  CH 223191 is an aryl hydrocarbon receptor antagonist that can help researchers interpret AhR-dependent transcription without confusing receptor activity with downstream inflammation. This article examines its value through the microbiota–tryptophan–AhR–stem cell model reported by Li et al., emphasizing causal interpretation, evidence limits, and translational relevance.

• Brain-to-Spinal Control of Opioid Pain Hypersensitivity

  2026-10-07

  Yin et al. identify a brain-to-spinal lPBN–PVH–spinal dorsal horn pathway that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study reframes mechanical opioid side effects as a circuit-level failure of spinal gate control and provides a mechanistic basis for interpreting κ-opioid receptor pharmacology in pain modulation research.

• α2-AR Agonism and Osteosarcoma Recurrence

  2026-10-06

  A 2025 preclinical study examined α2-adrenergic receptor activation delivered through a thermo-sensitive hydrogel as a strategy against post-surgical osteosarcoma recurrence. Its findings indicate that UK14,304 had limited direct effects on osteosarcoma cells in vitro but reduced recurrence in immunocompetent mice, consistent with an immune-mediated mechanism involving CD8+ T cells and T-cell receptor signaling.

• Matrine in Thymoma Research: Evidence and Limits

  2026-10-06

  Matrine, also indexed as Sophocarpidine, is a Sophora-derived alkaloid under investigation for anticancer and anti-inflammatory effects. A 2026 thymoma-cell study reported reduced viability, apoptosis induction, and suppression of stemness-associated phenotypes, while implicating YTHDF1 and Wnt/β-catenin signaling. The findings are promising but remain preclinical and mechanistically incomplete.

• ICAA, RIP3, and Cardiac Hypertrophy

  2026-10-05

  A 2026 Cellular Signalling study identifies isochlorogenic acid A as a regulator of RIP3-driven cardiac hypertrophy and connects this effect to CaMKII signaling. The preclinical findings suggest that the RIP3/CaMKII axis may complement established angiotensin II-centered models of cardiovascular disease research, while requiring validation in additional systems and human studies.

• Wnt/NR2F2 Links GPX4 to Platinum Resistance

  2026-10-05

  The reference study identifies a mechanistic link between Wnt/NR2F2 signaling, GPX4-dependent glutathione consumption, ferroptosis suppression, and acquired platinum resistance in lung cancer-derived brain metastasis. Its integrated preclinical and molecular evidence positions GPX4 and related redox dependencies as potential research targets, while the model and translational limitations require careful interpretation.

• How SARS-CoV-2 N Protein Disrupts GADD34 Signaling

  2026-10-04

  A 2024 Molecules study identifies a mechanism in which SARS-CoV-2 nucleocapsid protein redirects GADD34 mRNA into atypical G3BP1-positive foci, reducing GADD34-dependent IRF3 nuclear localization and interferon signaling. The findings refine current models of viral immune evasion by connecting stress-granule remodeling with post-transcriptional control of an innate immune regulator, while leaving important questions about physiological relevance and therapeutic translation.

• Neuroligin 1, D2-MSNs, and Repetitive Behavior

  2026-10-03

  The reference study links Neuroligin 1 loss in striatal D2-expressing medium spiny neurons to excessive self-grooming and digging through cell-specific hyperactivation and PKC-associated changes in neuronal excitability. Its multimodal evidence supports a circuit-level model of restricted and repetitive behavior, while its mouse-based design limits direct translation to human autism or clinical intervention.

• AMPK, ULK1, and Autophagy Under Energy Stress

  2026-10-02

  The reference study challenges the prevailing view that AMPK universally activates autophagy during energy shortage. Its experiments show that AMPK can suppress ULK1 initiation signaling while preserving the autophagy machinery, separating immediate energy-stress adaptation from later recovery.

• Tofacitinib in RA Macrophage Assays

  2026-10-01

  Learn how Tofacitinib and CP-690550 can separate JAK/STAT-dependent cytokine signaling from broader macrophage-state changes. This practical workflow covers dosing, mitochondrial readouts, controls, solubility, and troubleshooting for GM-CSF-reprogrammed rheumatoid arthritis models.

• Silymarin Workflows for Reproducible Bench Research

  2026-10-01

  Silymarin is a chemically diverse milk thistle extract that can support oxidative-stress, cancer, metabolic, and antiviral experiments when its solubility and batch composition are controlled. This practical guide pairs assay-ready preparation steps with orthogonal readouts and troubleshooting strategies to separate true biology from vehicle, precipitation, and mixture effects.

• Selonsertib (GS-4997): Designing Better Kidney Assays

  2026-09-30

  Selonsertib (GS-4997) is a selective ASK1 inhibitor for dissecting oxidative stress, inflammation, and fibrosis in kidney models. This article presents an assay-design framework based on lupus nephritis evidence, with practical controls and clear limits for translation to diabetic kidney disease research.

• Thermal-Protective Hydrogel for Curative Tumor Ablation

  2026-09-30

  The reference study introduces MR@CaP@HA, an injectable hydrogel that combines local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. By addressing collateral heat injury and weak post-ablation immunity in one platform, the system improved residual-tumor control and produced complete tumor eradication in a subset of treated animals.

• Recombinant Human Oncostatin M: Fibroblast Assays

  2026-09-29

  Use rh-Oncostatin M as a defined cytokine challenge to separate fibroblast proliferation, inflammatory release, and mitochondrial senescence phenotypes. This workflow combines a tag-free, low-endotoxin reagent with the 2025 dermal fibroblast study to build more discriminating stress, rescue, and dose-response experiments.

• WZ4003: A Context-Resolved NUAK1/2 Probe

  2026-09-29

  WZ4003 is a selective NUAK1/2 inhibitor for connecting kinase target engagement with migration, proliferation, invasion, and tau-phosphorylation phenotypes. This article explains how to design and interpret cross-domain assays without mistaking a downstream phenotype for proof of NUAK specificity.

8446 records 5/564 page Previous Next 12345 下5页 Last page